Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alkermes plc - Ordinary Shares (NQ: ALKS )

30.31 +0.21 (+0.70%)
Streaming Delayed Price Updated: 3:18 PM EST, Jan 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alkermes plc - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Happy New Year - Sunday Edition
Starting a new year - we look at tech, pharma and mining stocks and their goings-on. 
Via Talk Markets
Alkermes Has Launched Employee Resource Groups
SOURCE: Alkermes 
Via 3BL Media
Our Collective Responsibility to Respond Effectively to the Climate Crisis
SOURCE: Alkermes 
Via 3BL Media
Benzinga's Top Ratings Upgrades, Downgrades For December 1, 2021
Upgrades Goldman Sachs upgraded the previous rating for Grupo Aeroportuario del Sureste SAB de CV 
Via Benzinga
One Overdose Is Too Many
SOURCE: Alkermes 
Via 3BL Media
Alkermes in Action: Giving Tuesday
SOURCE: Alkermes 
Via 3BL Media
Exposures COVID-19
Alkermes Celebrates National Family Caregivers Month
SOURCE: Alkermes 
Via 3BL Media
75 Biggest Movers From Yesterday
Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep. Check out these big penny stock gainers and losers... 
Via Benzinga
Janssen Partially Terminates Nanoparticle License Agreement With Alkermes
Alkermes plc (NASDAQ: ALKS) stock is trading lower after announcing that Janssen, a unit of Johnson & Johnson (NYSE: JNJ), has provided notice of its... 
Via Benzinga
Why Alkermes Stock Is Sinking Today
Johnson & Johnson partly ended two licensing agreements with the company. 
Via The Motley Fool
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces... 
Via Benzinga
7 A-Rated Healthcare Stocks to Buy for the Long Haul
It looks like we're on the back end of the Covid pandemic, so it's a good time to look at healthcare stocks that have a big future. 
Via InvestorPlace
10 Biggest Price Target Changes For Thursday
Oppenheimer lowered Teladoc Health, Inc. (NYSE:TDOC 
Via Benzinga
Alkermes plc (ALKS) Q3 2021 Earnings Call Transcript
ALKS earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Cyber Currency
Canadian stocks are particularly buoyant and not just in energy which is a riser today because the loony is up against the buck. 
Via Talk Markets
Ketamine’s Potential As A Treatment For Depression Has Drawn Major Industry Attention
Palm Beach, FL –October 27, 2021 – FinancialNewsMedia.com News Commentary – Among the race to see what psychedelic drugs can do, ketamine is a step ahead of all other drugs, because it has already been... 
Via FinancialNewsMedia
Exposures Product Safety
Wednesday Market Coverage
Today gold rose again despite the active market for bitcoin and the lower Chinese demand for mine products like iron and coal. 
Via Talk Markets
The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More
Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength... 
Via Benzinga
Exposures Product Safety
Beam Therapeutics Stock Flashes Renewed Technical Strength
On Tuesday, Beam Therapeutics stock reached an key performance benchmark, seeing its RS Rating jump to 92, up from 88 the day before. 
Via Investor's Business Daily
Innoviva Stock In Buy Range; Joins Ranks Of Top-Performing Stocks With Strength Ratings Over 90
Innoviva stock is within a buy range after climbing above a 16.82 entry in a flat base. The proper buying range is up to 5% above the entry. 
Via Investor's Business Daily
Alkermes Stock Composite Rating Rises To Near-Perfect 96 As It Posts Erratic But Huge Sales Gains
The IBD SmartSelect Composite Rating for Alkermes rose from 94 to 96 Tuesday. 
Via Investor's Business Daily
Arcturus Therapeutics Stock Sees Relative Strength Rating Rise To 83
Arcturus Therapeutics sees its Relative Strength Rating hit the 80-plus level. 
Via Investor's Business Daily
Ligand Pharmaceuticals Stock Shows Rising Price Performance
A Relative Strength Rating upgrade for San Diego-based Ligand Pharmaceuticals stock shows improving technical performance. 
Via Investor's Business Daily
Acceleron Pharma Stock Meets 80-Plus Relative Strength Rating Benchmark
Want to build a watch list? Focus on stocks with an 80-plus RS Rating. Acceleron Pharma stock cleared that benchmark with an upgrade to 83. 
Via Investor's Business Daily
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7) Alkermes plc (NASDAQ: ALKS)... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug
Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks... 
Via Benzinga
Exposures Product Safety
Inmune Bio Stock Flashes Robust RS Rating
On Wednesday, Inmune Bio stock saw its Relative Strength Rating jump into the 90-plus percentile, to 92 from 85 the day before. 
Via Investor's Business Daily
New Survey Provides Insights Into Drinking Behaviors During the Pandemic
SOURCE: Alkermes 
Via 3BL Media
Exposures COVID-19
Recovery Month Renews Focus on Diagnosis, Treatment of Substance Use Disorder
SOURCE: Alkermes 
Via 3BL Media
Topics Death
Exposures Death
Ligand Pharmaceuticals Stock Shows Market Leadership With Jump To 82 RS Rating
Ligand Pharmaceuticals stock saw a positive improvement to its Relative Strength (RS) Rating on Monday, rising from 71 to 82. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.